CEACAM5 and cancer: IL-2v has been fused with several mAbs targeting PD-1 [42], carcinoembryonic antigen (CEA) [23], and fibroblast activation protein alpha (FAP), effectively targeting PD-1+ T cells, tumor cells, and cancer-associated fibroblasts, respectively.